P
Paul Sevelda
Researcher at University of Vienna
Publications - 123
Citations - 3782
Paul Sevelda is an academic researcher from University of Vienna. The author has contributed to research in topics: Breast cancer & Ovarian cancer. The author has an hindex of 28, co-authored 122 publications receiving 3473 citations.
Papers
More filters
Journal ArticleDOI
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
Martin Filipits,Margaretha Rudas,Raimund Jakesz,Peter Dubsky,Florian Fitzal,Christian F. Singer,Otto Dietze,Richard Greil,Andrea Jelen,Paul Sevelda,Christa Freibauer,Volkmar Müller,Fritz Jänicke,Marcus Schmidt,Heinz Kölbl,Achim Rody,Manfred Kaufmann,Werner Schroth,Hiltrud Brauch,Matthias Schwab,Peter Fritz,Karsten Weber,Inke Sabine Feder,Guido Hennig,Ralf Kronenwett,Mathias Gehrmann,Michael Gnant +26 more
TL;DR: A gene expression signature predicting the likelihood of distant recurrence in patients with estrogen receptor–positive, HER2-negative breast cancer treated with adjuvant endocrine therapy is developed and validated.
Journal ArticleDOI
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo- controlled trial
Michael Gnant,Georg Pfeiler,Peter Dubsky,Michael Hubalek,Richard Greil,Raimund Jakesz,Viktor Wette,Marija Balic,Ferdinand Haslbauer,Elisabeth Melbinger,Vesna Bjelic-Radisic,Silvia Artner-Matuschek,Florian Fitzal,Christian Marth,Paul Sevelda,Brigitte Mlineritsch,Günther G. Steger,Diether Manfreda,Ruth Exner,Daniel Egle,Jonas Bergh,Franz Kainberger,Susan Talbot,Douglas Warner,Christian Fesl,Christian F. Singer +25 more
TL;DR: Adjuvant denosumab 60 mg twice per year reduces the risk of clinical fractures in postmenopausal women with breast cancer receiving aromatase inhibitors, and can be administered without added toxicity.
Journal ArticleDOI
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
Michael Gnant,Brigitte Mlineritsch,Herbert Stoeger,G. Luschin-Ebengreuth,Michael Knauer,Martin Moik,Raimund Jakesz,Michael Seifert,Susanne Taucher,Vesna Bjelic-Radisic,Marija Balic,Holger Eidtmann,Wolfgang Eiermann,Günther G. Steger,Werner Kwasny,Peter Dubsky,U Selim,Florian Fitzal,Gerhard Hochreiner,Viktor Wette,Paul Sevelda,Ferdinand Ploner,Rupert Bartsch,Christian Fesl,Richard Greil +24 more
TL;DR: The final results from ABCSG 12 suggest that twice-yearly ZOL enhances the efficacy of adjuvant endocrine treatment, and this benefit is maintained long-term.
Journal Article
EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.
Fischer-Colbrie J,Armin Witt,Harald Heinzl,Paul Speiser,Klaus Czerwenka,Paul Sevelda,Robert Zeillinger +6 more
TL;DR: A significant correlation between EGFR positivity and a shorter progressive-free period as well as shorter overall survival was found and the impaired response of EGFR positive carcinomas to chemotherapy containing platinum compounds was indicated.
Journal ArticleDOI
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Gnant,Georg Pfeiler,Günther G. Steger,Daniel Egle,Richard Greil,Florian Fitzal,Viktor Wette,Marija Balic,Ferdinand Haslbauer,E. Melbinger-Zeinitzer,Vesna Bjelic-Radisic,Raimund Jakesz,Christian Marth,Paul Sevelda,Brigitte Mlineritsch,Ruth Exner,Christian Fesl,Sophie Frantal,Christian F. Singer,Austrian Breast +19 more
TL;DR: Results from the ABCSG-18 trial showed that use of denosumab as an adjuvant to aromatase inhibitor therapy significantly reduced clinical fractures.